(VIANEWS) – A10 Networks (ATEN), Ball Corporation (BLL), Primerica (PRI) are the highest sales growth and return on equity stocks on this list.

Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

1. A10 Networks (ATEN)

15.8% sales growth and 58.42% return on equity

A10 Networks, Inc. provides networking solutions in the United States, Japan, other Asia Pacific, and EMEA countries.

A10 Networks’s sales growth this year is anticipated to be 9.9% and 7.4% for next year.

Year-on-year quarterly revenue growth grew by 12.8%, now sitting on 250.04M for the twelve trailing months.

Volume

Today’s last reported volume for A10 Networks is 1094100 which is 24.84% above its average volume of 876396.

A10 Networks’s sales growth for the next quarter is 15.8%. The company’s growth estimates for the ongoing quarter and the next is 8.3% and 15.4%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 58.42%.

Volatility

A10 Networks’s last day, last week, and last month’s current intraday variation average was 0.43%, 2.52%, and 1.58%, respectively.

A10 Networks’s highest amplitude of average volatility was 6.85% (day), 7.10% (last week), and 5.15% (last month), respectively.

A10 Networks’s Stock Yearly Top and Bottom Value

A10 Networks’s stock is valued at $13.98 at 05:22 EST, way below its 52-week high of $19.05 and way higher than its 52-week low of $8.42.

A10 Networks’s Moving Average

A10 Networks’s value is below its 50-day moving average of $15.21 and higher than its 200-day moving average of $13.09.

2. Ball Corporation (BLL)

13.7% sales growth and 26.61% return on equity

Ball Corporation supplies aluminum packaging products to the beverage, personal care, automotive, paint, healthcare, and household products industries.

Ball Corporation’s sales growth this year is anticipated to be 15.6% and 8.3% for next year.

Year-on-year quarterly revenue growth grew by 23.5%, now sitting on 12.78B for the twelve trailing months.

Volume

Today’s last reported volume for Ball Corporation is 1664980 which is 12.52% below its average volume of 1903340.

Ball Corporation’s sales growth for the next quarter is 13.7%. The company’s growth estimates for the current quarter and the next is 12.4% and 22.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.61%.

Volatility

Ball Corporation’s last day, last week, and last month’s current intraday variation average was 0.64%, 0.98%, and 2.00%, respectively.

Ball Corporation’s highest amplitude of average volatility was 1.51% (day), 1.80% (last week), and 2.72% (last month), respectively.

Ball Corporation’s Stock Yearly Top and Bottom Value

Ball Corporation’s stock is valued at $94.05 at 05:22 EST, under its 52-week high of $98.09 and way above its 52-week low of $77.95.

Ball Corporation’s Moving Average

Ball Corporation’s value is above its 50-day moving average of $92.41 and higher than its 200-day moving average of $88.47.

3. Primerica (PRI)

13.3% sales growth and 22.87% return on equity

Primerica, Inc., together with its subsidiaries, provides financial products to middle income households in the United States and Canada.

Primerica’s sales growth this year is anticipated to be 22.6% and 8.3% for next year.

Year-on-year quarterly revenue growth grew by 21.6%, now sitting on 2.65B for the twelve trailing months.

Volume

Today’s last reported volume for Primerica is 110253 which is 19.86% below its average volume of 137581.

Primerica’s sales growth for the next quarter is 13.3%. The company’s growth estimates for the present quarter and the next is 31.4% and 20.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.87%.

Volatility

Primerica’s last day, last week, and last month’s current intraday variation average was 0.03%, 0.85%, and 1.01%, respectively.

Primerica’s highest amplitude of average volatility was 1.36% (day), 1.93% (last week), and 2.65% (last month), respectively.

Primerica’s Stock Yearly Top and Bottom Value

Primerica’s stock is valued at $153.75 at 05:22 EST, way below its 52-week high of $179.51 and higher than its 52-week low of $139.78.

Primerica’s Moving Average

Primerica’s worth is higher than its 50-day moving average of $151.67 and under its 200-day moving average of $154.81.

4. Danaher Corporation (DHR)

12.5% sales growth and 13.98% return on equity

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide.

Danaher Corporation’s sales growth this year is expected to be 28.7% and 5.4% for next year.

Year-on-year quarterly revenue growth grew by 36.3%, now sitting on 26.72B for the twelve trailing months.

Volume

Today’s last reported volume for Danaher Corporation is 2214840 which is 23.65% below its average volume of 2901220.

Danaher Corporation’s sales growth is a negative 0% for the present quarter and 12.5% for the next. The company’s growth estimates for the current quarter and the next is 25% and 14.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.98%.

Volatility

Danaher Corporation’s last day, last week, and last month’s current intraday variation average was 2.24%, 1.13%, and 1.57%, respectively.

Danaher Corporation’s highest amplitude of average volatility was 1.60% (day), 1.89% (last week), and 2.33% (last month), respectively.

Danaher Corporation’s Stock Yearly Top and Bottom Value

Danaher Corporation’s stock is valued at $292.01 at 05:22 EST, way below its 52-week high of $333.96 and way above its 52-week low of $211.22.

Danaher Corporation’s Moving Average

Danaher Corporation’s worth is under its 50-day moving average of $308.14 and above its 200-day moving average of $279.31.

5. New York Community Bancorp (NYCB)

9.7% sales growth and 9.28% return on equity

New York Community Bancorp, Inc. operates as a bank holding company for New York Community Bank that provides banking products and services in Metro New York, New Jersey, Ohio, Florida, and Arizona.

New York Community Bancorp’s sales growth this year is expected to be 17.3% and 45.6% for next year.

Year-on-year quarterly revenue growth grew by 18%, now sitting on 1.32B for the twelve trailing months.

Volume

Today’s last reported volume for New York Community Bancorp is 4642320 which is 24.1% below its average volume of 6117030.

New York Community Bancorp’s sales growth for the next quarter is 9.7%. The company’s growth estimates for the current quarter and the next is a negative 20.5% and 13.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.28%.

Volatility

New York Community Bancorp’s last day, last week, and last month’s current intraday variation average was 0.26%, 0.88%, and 1.22%, respectively.

New York Community Bancorp’s highest amplitude of average volatility was 2.85% (day), 2.59% (last week), and 2.99% (last month), respectively.

New York Community Bancorp’s Stock Yearly Top and Bottom Value

New York Community Bancorp’s stock is valued at $11.53 at 05:22 EST, way below its 52-week high of $14.33 and way higher than its 52-week low of $10.43.

New York Community Bancorp’s Moving Average

New York Community Bancorp’s worth is under its 50-day moving average of $12.25 and under its 200-day moving average of $12.25.

6. Alexion Pharmaceuticals (ALXN)

7.4% sales growth and 4.43% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals’s sales growth this year is anticipated to be 10.6% and 7% for next year.

Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 6.26B for the twelve trailing months.

Alexion Pharmaceuticals’s sales growth for the next quarter is 7.4%. The company’s growth estimates for the current quarter and the next is 7.1% and 4.6%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.43%.

Alexion Pharmaceuticals’s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals’s stock is valued at $0.00 at 05:22 EST, below its 52-week low of $99.91.

Alexion Pharmaceuticals’s Moving Average

Alexion Pharmaceuticals’s value is below its 50-day moving average of $182.75 and under its 200-day moving average of $165.77.

LEAVE A REPLY

Please enter your comment!
Please enter your name here